Skip to main content
. 2022 Nov 25;14(23):5815. doi: 10.3390/cancers14235815
ICI immune check point inhibitor
AFL ablative fractional laser
BCC basal cell carcinoma
Anti-PD1 anti-programmed death-1
MM malignant melanoma
TME tumor microenvironment
TILs tumor infiltrating lymphocytes
SCC squamous cell carcinoma
KC keratinocyte carcinoma
IHC immunohistochemistry
CR complete remission
LSR local skin reactions
AE adverse event